Shire plc (SHPG): $ Key Programs Not In Consensus - Jefferies
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Jefferies analyst, David Steinberg, reiterated his Buy rating on shares of Shire (NASDAQ: SHPG) after hosing 3 days of management meetings which increased his confidence that the company is well positioned to deliver ~15%+ EPS growth. In addition to many new data points on Xiidra, mgt expects that the hemophilia business will grow nicely – even if there is stiff competition in the inhibitor segment.
SHPG has 40+ programs in clinical testing and at least four late-stage programs appear overly discounted. Mgt projects sales of SHP465 of $500M+ by 2020; double that of consensus. This seems reasonable since every ADHD product launched has exceeded expectations. The second Ph3 asset is SHP621 for eosinophilic esophagitis. Given a dearth of therapies and ~180k US sufferers, peak sales could approach $500M yet Street models have no sales. Finally, expectations for IT programs (Hunters CNS, etc.) & SHP607 (Premiplex) have become heavily discounted due to mixed data or prior development setbacks. All four could become very meaningful products in the 2018-20 timeframe
No change to the price target of $262.
Shares of Shire closed at $192.37 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Cowen Downgrades Under Armour, Inc. (UA) to Market Perform
- Jefferies Remains Sidelined on Capital One Financial (COF) Following EPS Beat
- AK Steel (AKS) PT, Estimates Raised at Jefferies
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS View, Management Comments
Related EntitiesJefferies & Co
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!